The drug significantly outperformed the 8 per cent who were progression free at five years in a control group taking an alternative treatment called crizotinib, with the cancer spreading after 9.1 ...
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Crizotinib (Xalkori®), a small molecule kinase inhibitor, ...
Takeda has reported updated results from its ALTA-1L trial of Alunbrig (brigatinib) versus Xalkori (crizotinib) in first-line treatment of AK-positive non-small cell lung cancer (NSCLC), saying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback